[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337408-105":59,"doc-detail-337408-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pancreatic-neuroendocrine-tumors-signaling-pathways-and-epigenetic-regulation-review","Pancreatic Neuroendocrine Tumors - Signaling Pathways and Epigenetic Regulation - Review","","Pancreatic neuroendocrine tumors (PNETs) arise with dysregulated signaling pathways that drive tumor formation and progression, while traditional therapies show limited effectiveness, especially in advanced disease. Epigenetic alterations can reshape signaling pathway activity and create actionable opportunities for drug development. However, extensive epigenetic research in PNETs remains limited. This review summarizes key signaling events in PNET development and discusses how epigenetic regulation influences these pathways in PNETs and related malignancies, concluding with future research directions and patient-care applications.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pancreatic-neuroendocrine-tumors-signaling-pathways-and-epigenetic-regulation-review/337408/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pancreatic-neuroendocrine-tumors-signaling-pathways-and-epigenetic-regulation-review/337408.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What defines pancreatic neuroendocrine tumors in this review?","Question",{"text":112,"@type":113},"PNETs are described as rare, heterogeneous neoplasms from pancreatic islet cells, characterized by dysregulated signaling pathways that support tumor formation, progression, and potential metastasis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does epigenetic regulation relate to signaling pathways in PNETs?",{"text":117,"@type":113},"Epigenetic alterations can profoundly affect signaling pathway activity during cancer development, creating opportunities for targeted drug development even though extensive PNET-specific epigenetic research is still limited.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the grading classification change mentioned for PNENs?",{"text":121,"@type":113},"The review notes that the W.H.O. revised the grading of pancreatic neuroendocrine neoplasms in 2019 by dividing the former G3 group into PNET G3 and pancreatic neuroendocrine carcinomas (PNECs), reflecting distinct clinical and molecular entities.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337408,1792193634,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","Review  \nPancreatic Neuroendocrine Tumors: Signaling Pathways and Epigenetic Regulation  \nZena Saleh 1,†, Matthew C. Moccia 1,†, Zachary Ladd 1, Upasana Joneja 2, Yahui Li 1, Francis Spitz 1, Young Ki Hong 1,* and Tao Gao 1,3, *  \n1 Department of Surgery, Cooper University Health Care, Camden, NJ 08103, USA; [saleh-zena@cooperhealth.edu](saleh-zena@cooperhealth.edu) (Z.S.); [laddza45@rowan.edu](laddza45@rowan.edu) (Z.L.)  \n2 Department of Pathology, Cooper University Health Care, Camden, NJ 08103, USA  \n3 Camden Cancer Research Center, Camden, NJ 08103, USA  \n* [Correspondence: hong-young@cooperhealth.edu](Correspondence: hong-young@cooperhealth.edu) (Y.K.H.); [gao-tao@cooperhealth.edu](gao-tao@cooperhealth.edu) (T.G.)† These authors contributed equally to this work.  \nAbstract: Pancreatic neuroendocrine tumors (PNETs) are characterized by dysregulated signaling pathways that are crucial for tumor formation and progression. The efficacy of traditional therapies is limited, particularly in the treatment of PNETs at an advanced stage. Epigenetic alterations profoundly impact the activity of signaling pathways in cancer development, offering potential opportunities for drug development. There is currently a lack of extensive research on epigenetic regulation in PNETs. To fill this gap, we first summarize major signaling events that are involved in PNET development. Then, we discuss the epigenetic regulation of these signaling pathways in the context of both PNETs and commonly occurring—and therefore more extensively studied—malignancies. Finally, we will offer a perspective on the future research direction of the PNET epigenome and its potential applications in patient care.  \nCitation: Saleh, Z.; Moccia, M.C.; Ladd, Z.; Joneja, U.; Li, Y.; Spitz, F.; Hong, Y.K.; Gao, T. Pancreatic Neuroendocrine Tumors: Signaling Pathways and Epigenetic Regulation. Int. J. Mol. Sci. 2024, 25, 1331. [https://](https://)[ ](https://)[doi.org/10.3390/ijms25021331](doi.org/10.3390/ijms25021331)  \nAcademic Editors: Benjamin Frey, Dorota Lubgan and Nathalie Britzen-Laurent  \nReceived: 20 December 2023  \nRevised: 12 January 2024  \nAccepted: 16 January 2024  \nPublished: 22 January 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nKeywords: pancreatic neuroendocrine tumors; signaling pathways; epigenetic regulation  \n1. Introduction  \nPancreatic neuroendocrine tumors (PNETs) are a rare and heterogeneous group of neoplasms arising from pancreatic islet cells. They account for approximately 2% of all pancreatic malignancies and are characterized by their slow-growing nature and potential for metastasis [1] . Current treatment options for PNETs are limited, and the prognosis for patients with advanced disease remains poor, underscoring the urgent need for innovative therapeutic strategies [2] . PNETs were originally classified into three distinct categories:  \n(1) G1, which are well-differentiated PNETs and characterized by mitoses \u003C2/10 highpower field (HPF) and Ki67 index \u003C3%; (2) G2, which are well-differentiated PNETs with mitoses ranging from 2 to 20/10 HPF or Ki67 index between 3% and 20%; (3) G3, which are poorly differentiated and also called pancreatic neuroendocrine carcinomas (PNECs) with mitoses exceeding 20/10 HPF or Ki67 index surpassing 20% . Over the years, advancementsin clinical practice and research, particularly in next-generation sequencing and analysis, have led to the recognition that the G3 group comprises at least two distinct subtypes—the well-differentiated PNET G3 and poorly differentiated PNECs—which are genetically different from each other [3] . In 2019, the W.H.O. revised the grading classification of pancreatic ne","cbCaik7Dp9eTfI4w","https://ap.wps.com/l/cbCaik7Dp9eTfI4w","pdf",766484,35,"English","# Introduction\n## Classification and grading of pancreatic neuroendocrine neoplasms\n# Abstract and scope of the review\n# Signaling pathway events in PNET development\n# Epigenetic regulation of signaling pathways\n# Future research directions and patient care applications","[{\"question\":\"What defines pancreatic neuroendocrine tumors in this review?\",\"answer\":\"PNETs are described as rare, heterogeneous neoplasms from pancreatic islet cells, characterized by dysregulated signaling pathways that support tumor formation, progression, and potential metastasis.\"},{\"question\":\"How does epigenetic regulation relate to signaling pathways in PNETs?\",\"answer\":\"Epigenetic alterations can profoundly affect signaling pathway activity during cancer development, creating opportunities for targeted drug development even though extensive PNET-specific epigenetic research is still limited.\"},{\"question\":\"What is the grading classification change mentioned for PNENs?\",\"answer\":\"The review notes that the W.H.O. revised the grading of pancreatic neuroendocrine neoplasms in 2019 by dividing the former G3 group into PNET G3 and pancreatic neuroendocrine carcinomas (PNECs), reflecting distinct clinical and molecular entities.\"}]","Pancreatic Neuroendocrine Tumors - Signaling Pathways and Epigenetic Regulation - Review | PDF",1790019006,88,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/51ef5d45f29234a9a4caa0a2c9036b23.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/26886e88cffc11e33dc791598f6e53cd.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f73a3d3b7df395b9c6085b0e9269e34d.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d38c4ff9b10b34b58eba77fb602fc84b.webp",980,1385]